The key to achieving solid long-term investment returns lies in paying attention to the valuation levels of stocks. Even a company with excellent fundamentals can lead to limited gains or even losses if one pays too high a premium. Therefore, reasonable valuation is a crucial part of the investment decision-making process.
An effective method to assess stock value is to focus on its forward price-to-earnings (P/E) ratio, which is the P/E multiple calculated based on analysts’ earnings forecasts for the next year. Compared to the trailing P/E ratio that only reflects past performance, the forward P/E ratio more proactively captures a company’s growth potential and avoids excessive interference from single-quarter earnings fluctuations.
The forward P/E ratio of healthcare company AbbVie is slightly below 16x, notably lower than the S&P 500’s average of approximately 22x. More importantly, its long-term price/earnings-to-growth (PEG) ratio is around 0.40, well below the 1x threshold typically considered indicative of an investable growth stock. This suggests the stock offers outstanding valuation appeal from a medium-to-long-term growth perspective. The company’s R&D pipeline covers about 90 different compounds, devices, or indications, with roughly 60 projects in mid- to late-stage development. This sustained R&D investment lays a solid foundation for its future growth. In the first nine months of this fiscal year, AbbVie generated revenue of $44.5 billion, an 8% year-over-year increase, with operating profit reaching $10.5 billion. The company previously projected it would maintain high-single-digit growth through the end of this decade, and its current development momentum supports the achievement of this target.
Despite Micron Technology’s stock price rising significantly over the past 12 months, its forward P/E ratio remains at just 11x, with a PEG ratio of 0.6, indicating its valuation is still attractive relative to its growth expectations. Strong market demand for memory and storage products has led the company to decide to exit the consumer business and focus on the enterprise market. Driven by the artificial intelligence (AI) and data center construction wave, its enterprise business is experiencing rapid growth. Over the past four quarters, the company’s total revenue reached $42.3 billion, with net profit at $11.9 billion, yielding a high net profit margin of 28%. By concentrating on faster-growing segments, Micron Technology’s financial performance is expected to further improve following its business realignment.
Amid the AI investment boom, Adobe’s stock performance has been overlooked, declining about 19% over the past 12 months. Its forward P/E ratio is now only 14x, with a PEG ratio slightly below 1. Although the market has concerns about its competitive position in AI tools, the company’s financial performance remains solid. In the most recent fiscal year, Adobe achieved total revenue of $23.8 billion, an 11% year-over-year increase, with net profit reaching $7.1 billion, up 28% year-over-year. The company maintains a high gross margin of around 90%, which preserves room for price adjustments if necessary to maintain competitiveness, though no price cuts are currently planned, demonstrating business stability. Market concerns about the impact of AI might be excessive, and the current valuation may already reflect pessimistic expectations, presenting an opportunity for growth-oriented investors to take note.
In summary, AbbVie, Micron Technology, and Adobe all demonstrate a favorable combination of valuation and growth potential. Through analysis using metrics like the forward P/E ratio, these companies possess solid fundamentals and promising growth prospects in their respective fields, making them worthy of investor attention under the premise of prioritizing valuation.
